Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma.
OBJECTIVE
To determine activity and toxicity of high-dose ifosfamide (HDIFO) in recurrent or advanced Ewing sarcoma family tumors (EFT).


METHODS
Thirty-seven EFT patients [median age 17 years (6-45 years)] previously treated with chemotherapy regimens including standard dose ifosfamide were enrolled. HDIFO was administered for metastatic recurrent disease in 33 patients and for progression during neoadjuvant chemotherapy in 4 patients. All patients who received two courses of 15 g/m(2) ifosfamide were evaluable for radiographic response assessed according to RECIST criteria.


RESULTS
Transient Grade 4 neutropenia and thrombocytopenia in 97% and 54% HDIFO courses respectively and severe CNS toxicity in one patient were observed. Thirty-five patients were evaluable: 12 (34%) had complete (2) or partial (10) response, 11 (32%) had stable disease, and 12 (34%) had progression.


CONCLUSIONS
In patients with relapsed or advanced EFT previously treated with standard dose ifosfamide HDIFO is active and it should be considered a treatment option.
Ferrari
S
S
Department Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy. stefano.ferrari@ior.it
del Prever
A Brach
AB
Palmerini
E
E
Staals
E
E
Berta
M
M
Balladelli
A
A
Picci
P
P
Fagioli
F
F
Bacci
G
G
Vanel
D
D
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012008:Recurrence; D012512:Sarcoma, Ewing / Q000188:drug therapy* / Q000473:pathology*
D000970:Antineoplastic Agents; D007069:Ifosfamide